{"id":"W2182872902","doi":"10.1111/bjh.13855","title":"A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone ( <scp>CEOP</scp> ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( <scp>PTCL</scp> ): final results from the T‐ cell consortium trial","year":2015,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Genentech; Spectrum Pharmaceuticals","keywords":"Vincristine; Etoposide; Medicine; Cyclophosphamide; Prednisone; Lymphoma; Internal medicine; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001247403,0.001285855,0.001173672,0.0004633905,0.0003119662,0.0007912031,0.0005703404,0.001027533,0.002599684],"category_scores_gemma":[0.0005834158,0.0004077181,0.001101479,0.0002952734,0.0007014615,0.0006266548,0.0002904371,0.002334121,0.0004504673],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007456295,"about_ca_system_score_gemma":0.001102977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009182855,"about_ca_topic_score_gemma":0.002379544,"domain_scores_codex":[0.9996839,0.0001657837,0.00001316814,0.00004768703,0.00003084572,0.00005871896],"domain_scores_gemma":[0.9994839,0.0001033498,0.00009292184,0.00004578811,0.00002734793,0.0002466044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.787361,0.05425408,0.004717196,0.0007451217,0.001371284,0.0002994911,0.0002564827,0.002840083,0.04005881,0.0004719964,0.004154267,0.1034702],"study_design_scores_gemma":[0.6681331,0.3190626,0.005493468,0.00002880809,0.0003905949,0.0002260396,0.00003495874,0.001134154,0.002996094,0.0002183065,0.002260328,0.00002154925],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935713,0.001322603,0.0003882683,0.0003349237,0.0001045872,0.001875475,0.0006345334,0.000067625,0.001700735],"genre_scores_gemma":[0.9887567,0.00156817,0.001678042,0.001008528,0.0002122285,0.001903807,0.002038538,0.00003186932,0.00280207],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002599684,"threshold_uncertainty_score":0.008696795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02110693813914477,"score_gpt":0.2709042396403967,"score_spread":0.249797301501252,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}